Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김혜진 | - |
dc.contributor.author | 정인경 | - |
dc.contributor.author | 허규연 | - |
dc.contributor.author | 김수경 | - |
dc.contributor.author | 노정현 | - |
dc.contributor.author | 전성완 | - |
dc.contributor.author | 강은석 | - |
dc.contributor.author | 이은정 | - |
dc.contributor.author | 최성희 | - |
dc.date.accessioned | 2022-11-29T06:41:43Z | - |
dc.date.available | 2022-11-29T06:41:43Z | - |
dc.date.created | 2022-11-28 | - |
dc.date.issued | 2022-09 | - |
dc.identifier.issn | 2233-6079 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/21877 | - |
dc.description.abstract | Background: The choice of an optimal oral hypoglycemic agent in the initial treatment periods for type 2 diabetes mellitus (T2DM) patients remains difficult and deliberate. We compared the efficacy and safety of glimepiride (GLIM), alogliptin (ALO), and alogliptin-pioglitazone (ALO-PIO) in poorly controlled T2DM patients with drug-naïve or metformin failure.Methods: In this three-arm, multicenter, open-label, randomized, controlled trial, poorly controlled T2DM patients were randomized to receive GLIM (<i>n</i>=35), ALO (<i>n</i>=31), or ALO-PIO (<i>n</i>=33) therapy for 24 weeks. The primary endpoint was change in the mean glycosylated hemoglobin (HbA1c) levels at week 24 from baseline. Secondary endpoints were changes in HbA1c level at week 12 from baseline, fasting plasma glucose (FPG) levels, lipid profiles at weeks 12 and 24, and parameters of glycemic variability, assessed by continuous glucose monitoring for 24 weeks.Results: At weeks 12 and 24, the ALO-PIO group showed significant reduction in HbA1c levels compared to the ALO group (–0.96%±0.17% vs. –0.37%±0.17% at week 12; –1.13%±0.19% vs. –0.18%±0.2% at week 24). The ALO-PIO therapy caused greater reduction in FPG levels and significant increase in high-density lipoprotein cholesterol levels at weeks 12 and 24 than the ALO therapy. Compared to low-dose GLIM therapy, ALO-PIO therapy showed greater improvement in glycemic variability. The adverse events were similar among the three arms.Conclusion: ALO-PIO combination therapy during the early period exerts better glycemic control than ALO monotherapy and excellency in glycemic variability than low-dose sulfonylurea therapy in uncontrolled, drug-naïve or metformin failed T2DM patients. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 대한당뇨병학회 | - |
dc.title | Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study | - |
dc.title.alternative | Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 전성완 | - |
dc.identifier.doi | 10.4093/dmj.2021.0183 | - |
dc.identifier.scopusid | 2-s2.0-85130413344 | - |
dc.identifier.wosid | 000910538100004 | - |
dc.identifier.bibliographicCitation | Diabetes and Metabolism Journal, v.46, no.5, pp.689 - 700 | - |
dc.relation.isPartOf | Diabetes and Metabolism Journal | - |
dc.citation.title | Diabetes and Metabolism Journal | - |
dc.citation.volume | 46 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 689 | - |
dc.citation.endPage | 700 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002878700 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.subject.keywordPlus | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | - |
dc.subject.keywordPlus | IMPROVES GLYCEMIC CONTROL | - |
dc.subject.keywordPlus | COMBINATION THERAPY | - |
dc.subject.keywordPlus | LIPID PROFILES | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | THIAZOLIDINEDIONES | - |
dc.subject.keywordPlus | ROSIGLITAZONE | - |
dc.subject.keywordPlus | SULFONYLUREAS | - |
dc.subject.keywordPlus | VARIABILITY | - |
dc.subject.keywordPlus | METFORMIN | - |
dc.subject.keywordAuthor | Alogliptin | - |
dc.subject.keywordAuthor | Diabetes mellitus | - |
dc.subject.keywordAuthor | type 2 | - |
dc.subject.keywordAuthor | Glimepiride | - |
dc.subject.keywordAuthor | Glycemic control | - |
dc.subject.keywordAuthor | Pioglitazone | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.